<SEC-DOCUMENT>0001193125-23-202937.txt : 20230803
<SEC-HEADER>0001193125-23-202937.hdr.sgml : 20230803
<ACCEPTANCE-DATETIME>20230803164200
ACCESSION NUMBER:		0001193125-23-202937
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230802
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230803
DATE AS OF CHANGE:		20230803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		231140836

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d522240d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:staa="http://www.staar.com/20230802" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2023-08-02_to_2023-08-02">STAAR SURGICAL CO</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-08-02_to_2023-08-02">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-08-02_to_2023-08-02">0000718937</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="staa-20230802.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-08-02_to_2023-08-02"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000718937</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-02</xbrli:startDate> <xbrli:endDate>2023-08-02</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, DC 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-08-02_to_2023-08-02">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-08-02_to_2023-08-02" format="ixt:datemonthdayyearen">August 2, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">STAAR Surgical Company</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-08-02_to_2023-08-02" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-08-02_to_2023-08-02">0-11634</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-08-02_to_2023-08-02">95-3797439</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-08-02_to_2023-08-02">25651 Atlantic Ocean Drive</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-08-02_to_2023-08-02">Lake Forest</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-08-02_to_2023-08-02" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-08-02_to_2023-08-02">92630</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <span style="text-decoration:underline"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-08-02_to_2023-08-02">626</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-08-02_to_2023-08-02">303-7902</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-style:italic">see </span>General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-08-02_to_2023-08-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-08-02_to_2023-08-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-08-02_to_2023-08-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-08-02_to_2023-08-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-08-02_to_2023-08-02">Common</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-08-02_to_2023-08-02">STAA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-08-02_to_2023-08-02" format="ixt-sec:exchnameen">NASDAQ</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-08-02_to_2023-08-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;7.01 Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;2, 2023, the Company held a conference call to discuss the financial results for the quarter ended June&#160;30, 2023. A transcript of the conference call is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report, and Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 Financial Statements and Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d522240dex991.htm">Transcript of conference call of the Company held on August&#160;2, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:15%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:37%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:37%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="7">STAAR Surgical Company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">August&#160;3, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tom Frinzi</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Thomas G. Frinzi</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d522240dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>REFINITIV STREETEVENTS<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EDITED TRANSCRIPT</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STAA.OQ - Q2 2023 STAAR Surgical Co
Earnings Call </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EVENT DATE/TIME: AUGUST 02, 2023 / 8:30PM GMT </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATE PARTICIPANTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Brian</B><B> </B><B>Moore</B><B> </B>STAAR Surgical Company - VP of Investor, Media Relations&nbsp;&amp; Corporate Development </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick</B><B> </B><B>F.</B><B> </B><B>Williams</B><B> </B>STAAR Surgical Company - CFO </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas</B><B> </B><B>G.</B><B> </B><B>Frinzi</B><B> </B>STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONFERENCE CALL PARTICIPANTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anthony Charles
Petrone</B> Mizuho Securities USA LLC, Research <FONT STYLE="white-space:nowrap">Division-MD</FONT> &amp; Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bruce</B><B> </B><B>David</B><B> </B><B>Jackson</B><B> </B>The Benchmark Company, LLC, Research Division - Senior Equity Analyst </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>David</B><B> </B><B>Joshua</B><B> </B><B>Saxon</B><B> </B>Needham&nbsp;&amp; Company, LLC, Research Division - Senior Analyst </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James</B><B> </B><B>Philip</B><B> </B><B>Sidoti</B><B> </B>Sidoti&nbsp;&amp; Company, LLC - Research Analyst </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Malgorzata</B><B> </B><B>Maria</B><B> </B><B>Kaczor</B><B> </B><B>Andrew</B><B> </B>William Blair&nbsp;&amp; Company L.L.C., Research Division -
Partner&nbsp;&amp; Research Analyst </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steven</B><B> </B><B>Michael</B><B> </B><B>Lichtman</B><B> </B>Oppenheimer&nbsp;&amp; Co. Inc., Research Division
- MD&nbsp;&amp; Senior Analyst </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas</B><B> </B><B>M.</B><B> </B><B>Stephan</B><B> </B>Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, Research
Division - Associate </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Xuyang</B><B> </B><B>Li</B><B> </B>Jefferies LLC, Research Division - Equity Analyst </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRESENTATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Second Quarter Financial Results Conference Call. (Operator
Instructions) This call is being recorded today, Wednesday, August&nbsp;2, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this time, I would like to turn the conference over to Mr.&nbsp;Brian
Moore, Vice President, Investor, Media Relations and Corporate Development for STAAR Surgical. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Brian Moore </B>- STAAR Surgical Company - VP of
Investor, Media Relations&nbsp;&amp; Corporate Development </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you, operator, and good afternoon, everyone. Thank you for joining us on the STAAR
Surgical conference call this afternoon to discuss the company&#146;s financial results for the second quarter ended June&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the call
today are Tom Frinzi, President and Chief Executive Officer; and Patrick Williams, Chief Financial Officer. The press release of our second quarter results was issued just after 4:00 p.m. Eastern Time and is now available on STAAR&#146;s website at
www.staar.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking
statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company&#146;s projections, expectations, plans, beliefs and prospects. These statements are
based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The
risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the safe harbor statement in today&#146;s press release as well as STAAR&#146;s public periodic filings with the SEC.
Except as required by law, STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, to supplement the GAAP numbers, we have provided Non-GAAP Adjusted Net Income, Adjusted Net
Income for ICL, the corresponding Adjusted Earnings per share and Sales in Constant Currency. During the quarter, the company also reported various accounting adjustments related to its other product, cataract IOL business. Please refer to the <FONT
STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures tables to Adjusted Net Sales, Adjusted Cost of Sales, Adjusted Gross Profit Margin, Adjusted Operating Expenses and Adjusted Income Tax Provision. We believe that these <FONT
STYLE="white-space:nowrap">Non-GAAP</FONT> and adjusted numbers provide meaningful supplemental information and are helpful in assessing our historical and future performance. A table reconciling the GAAP information to the <FONT
STYLE="white-space:nowrap">Non-GAAP</FONT> information is included in today&#146;s press release. For brevity, all references to growth rates on today&#146;s call refer to year-over-year growth unless otherwise stated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following our prepared remarks, we will open the line to questions from publishing analysts. We ask analysts limit themselves to two initial questions, then <FONT
STYLE="white-space:nowrap">re-queue</FONT> with any <FONT STYLE="white-space:nowrap">follow-ups.</FONT> We thank everyone in advance for their cooperation with this process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And with that, I would like to now turn the call over to Tom Frinzi, President and CEO of STAAR. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you, Brian, and good afternoon, everyone, and thank you for joining us on today&#146;s call. I am pleased to report STAAR achieved record sales and
profitable growth for the second quarter 2023. Results were driven by our EVO family of proprietary Implantable Collamer Lenses, ICLs, which are designed to correct refractive error for people seeking visual freedom from the hassles of contacts and
eyeglasses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the second quarter of 2023, total ICL sales were $93.1&nbsp;million were in line with the outlook of approximately $93&nbsp;million that
we provided on our last earnings call in May. Globally, ICL sales growth in the second quarter was up 19% as reported and up 20% in Constant Currency. Global ICL unit growth was up 21% with results in the second quarter driven by strength in APAC,
the largest region for refractive procedures. APAC was up 29% in units and 26% in sales for the second quarter of 2023. In China specifically, ICL units were up 35% and sales up 33% for the second quarter of 2023. And we are encouraged by a strong
start to the peak implant season for ICLs in that market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the second quarter, sales in our EMEA region declined 9%, impacted by the ongoing
macroeconomic and geopolitical environment, as well as an inability to ship ICLs into 1 <FONT STYLE="white-space:nowrap">non-European</FONT> country as a result of a country-specific product labeling change. However, looking at European markets
only, ICL units were up 6% and sales up 2% for the second quarter of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Turning attention to the United States. ICL sales grew 10% for the second
quarter, well ahead of U.S. refractive industry procedure volumes, which the Refractive Surgery Council recently reported declines approximately 15% in the quarter. Sequentially, our U.S. sales in the second quarter were relatively flat. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lower than expected results in the U.S., the macroeconomic impact in Europe and certain other refractive markets merits additional conservatism as we look to
the second half of 2023. We have therefore today updated our fiscal 2023 ICL sales outlook to a range of approximately $320&nbsp;million to $325&nbsp;million. At the midpoint, our new outlook represents a high level of sales growth at approximately
20%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since becoming CEO in January, I have now had the opportunity to make a more complete assessment of the business in the U.S. and around the world.
We have implemented a high-performance management system that helps us get closer to our customers and other stakeholders and identify top priorities for accelerating EVO adoption. We have created cross-functional teams for each top priority who are
accountable for achieving the desired results. Among the priorities and actions we have taken to accelerate adoption in the U.S. and globally are the following. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number 1, we&#146;ve enhanced our leadership in April, appointing 2 seasoned executives, Warren Foust as Chief Operating Officer; and Magda Michna as Chief
Clinical, Regulatory and Medical Affairs Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number 2, we are taking actions to make our company even easier to do business with. The projects
related to this top priority are focused on increasing surgeon confidence in measurement and lens size selection, simplifying our ordering process, delivering our lenses to customers faster, and longer term, making the EVO ICL even easier to deliver
to the eye. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number 3, we have developed and are implementing new analytic tools, which is allowing us to better target
high volume customers with favorable economics. For example, we have mapped the over 430 practices representing our <FONT STYLE="white-space:nowrap">600-plus</FONT> surgeon customers in the U.S., and as a result, we are implementing tailored
programs that effectively leverage the knowledge we have gained from these tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number 4, we will pilot a patient call center education and surgeon
referral program aimed at better answering patient questions and shepherding patients to the most appropriate EVO customers. We believe the call center will create a closed loop for our patient Doc Finder, allowing us to better support and track the
patient journey and thereby better monitor the effectiveness of our investment in the U.S. in consumer awareness and other activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate the
actions and projects I just outlined, among others, will accelerate EVO adoption in the U.S. as we exit 2023 and beyond. Our vital few priorities and our learnings in the U.S. will also have positive implications for our markets globally. So while
I&#146;ve previously stated that laser vision correction is well established, I remain confident in EVO&#146;s ability to be successful in the U.S. and beyond. And my confidence is buoyed as I spent time in the field with key opinion leaders
discussing the impact that EVO is and can have on their practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The investment rationale for STAAR remains compelling. We have a fantastic technology
without peer. If you define good medicine as I do &#151; excellent patient outcomes, high patient and surgeon satisfaction, and favorable economics &#151; EVO is indeed good medicine. STAAR is the dominant player globally in lens-based refractive
vision correction for 21 to 60 year olds who are facing an increasing epidemic of myopia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Next, we expect to remain a high growth company based on our
strength in APAC, the largest region for refractive procedures in the world. Additional growth will come as we deliver similar results in the U.S., the second largest market for refractive procedures in the world, and Europe emerges from the current
macro and geopolitical headwinds. And finally, we are profitable, we generate cash and we have a rock solid balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For those of you that would
like to learn more, we will host an Investor and Analyst Meeting in New York next month on September&nbsp;14 where we will outline in more detail initiatives, projects, including some next-generation product pipeline initiatives, and the significant
growth opportunities ahead for STAAR. We also expect to have several EVO surgeons from around the world who will speak to their experience. Patrick? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company -
CFO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you, Tom, and good afternoon, everyone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before I
go through the various financial metrics, I want to reference additional <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> reconciliation tables in this quarter&#146;s earnings release. As we have previously mentioned on prior earnings calls and in
our filings, we are exiting our other product, cataract IOL business, as we focus on our core ICL products. This resulted in some accounting adjustments, primarily due to excess inventory and a smaller sales return reserve adjustment. Please refer
to the <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures tables in our earnings release as I will be referencing both as reported and adjusted impact in my prepared comments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total net sales for Q2 2023 were $92.3&nbsp;million, up 14% as compared to the $81.1&nbsp;million of net sales in Q2 2022 and up 26% on a sequential basis
from Q1 2023 net sales of $73.5&nbsp;million. The year-over-year increase in net sales is attributable to a $50&nbsp;million or a 19% increase in ICL sales, partially offset by a $4&nbsp;million decrease in other product sales. This included a
$742,000 sales return reserve adjustment, or reduction in sales, for our other product cataract IOL business, resulting in adjusted net sales of $93&nbsp;million or up 15% year-over-year. We continue to expect other products will represent a smaller
and smaller percentage of net sales as we move through fiscal 2023 and taper our support of this <FONT STYLE="white-space:nowrap">non-core</FONT> cataract IOL business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross profit for Q2 2023 was $70.7&nbsp;million, or 76.6% of net sales, as compared to gross profit of $63.9&nbsp;million, or 78.8% of net sales, for Q2 2022,
and $57.6&nbsp;million or 78.3% of net sales for Q1 2023. The 220 basis point decrease in gross margin as compared to Q2 2022 is primarily due to inventory reserves related to the other product cataract IOL business. The 170 basis point sequential
decrease in gross margin from the first quarter is also due to the other product cataract IOL inventory reserve. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">4</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amount of additional inventory reserves was $2.8&nbsp;million, and when adjusted, our gross margin
was 79.8% in the quarter. Due to the additional IOL reserves booked in the second quarter, but primarily driven by the lower sales outlook for fiscal 2023, we now expect gross margin will be approximately 79% for both Q3 and Q4 and approximately 78%
for the full year. We continue to drive initiatives to improve our manufacturing efficiency. When combined with more favorable geographic mix related to direct markets like the United States, we believe company gross margins can exceed 80% as we
move beyond 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moving down the income statement. Total operating expenses for Q2 2023 were $62.1&nbsp;million as compared to $46.9&nbsp;million in Q2
2022 and $54.8 million in Q1 2023. This included $154,000 intangible asset impairment adjustment related to our other product cataract IOL business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taking a closer look at the components of operating expenses. G&amp;A expense for Q2 2023 was $18.1&nbsp;million compared to $14&nbsp;million for Q2 2022 and
$18.1&nbsp;million for Q1 2023. The year-over-year increase in G&amp;A is due to increased compensation-related expenses, outside services and facilities costs. For fiscal 2023, we continue to expect G&amp;A expense will be approximately
$19&nbsp;million per quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling and marketing expense was $32.3&nbsp;million for Q2 2023 compared to $24.2&nbsp;million for Q2 2022 and
$26.4&nbsp;million for Q1 2023. The increase in selling and marketing expense from the prior year was due to increased advertising and promotional expenses, compensation-related expenses, trade shows and meetings. The sequential increase in selling
and marketing was due to increased advertising and promotional expense, trade shows and meetings and compensation-related expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we have said
before, driving EVO adoption is a multi-pronged approach focused on physician training and confidence, along with increased brand awareness through our marketing efforts. We are not seeing the type of returns on our digital marketing investments
that we had expected and have thus made the decision to reduce such investments until we can be more certain that patient conversion and the overall cost of patient acquisition meets our internal targets. Thus, we now expect selling and marketing
expenses will be approximately $30&nbsp;million in Q3 and $27&nbsp;million in Q4, down from approximately $33&nbsp;million each quarter previously. As we have said, the ability to flex our digital marketing investment allows us to react quickly to
the market, and we will revisit this as we move beyond 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense was $11.8&nbsp;million in Q2 2023 compared to
$8.6&nbsp;million for Q2 2022 and $10.3&nbsp;million for Q1 2023. The year-over-year and sequential increase in R&amp;D is due to increased compensation-related expenses and U.S. EVO post-approval clinical trial expenses associated with the <FONT
STYLE="white-space:nowrap">3-year</FONT> study. For fiscal 2023, we now expect R&amp;D expense will be slightly higher at approximately $12&nbsp;million for Q3 and Q4 as we have made additional investments in our clinical and medical affairs, which
falls under R&amp;D, as we look to drive increased physician confidence through training, publications and other clinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating income in Q2
2023 was $8.6&nbsp;million, or 9.3% of net sales, as compared to $17&nbsp;million, or 21% of net sales for Q2 2022. We now anticipate other income expense will be slightly down at approximately $500,000 of income per quarter for the balance of the
year, primarily due to foreign exchange gain losses that are booked on this line item. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We remain proud of our multiyear track record of profitability and
cash generation, which we expect to continue and is rare for a high-growth medical device company. The reduction in our sales outlook for the full year and being primarily in high gross margin direct markets like the United States does reduce our
overall operating income. But when partially offset with the reduction in sales and marketing investments, we now expect operating margin for the fiscal year 2023 will be approximately 5%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net income in Q2 2023 was $6.1&nbsp;million, or $0.12 per diluted share, compared to net income of $13&nbsp;million, or $0.26 per diluted share in Q2 2022.
After taking into account the aforementioned adjustments related to our other product cataract IOL business, as well as a $405,000 tax effected benefit from those adjustments, our adjusted net income for ICL was $9.4&nbsp;million, or $0.19 per
diluted share. Tables reconciling the GAAP to <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> information and IOL accounting adjustments are included in today&#146;s financial release. For fiscal 2023, we now expect our effective tax rate will be
slightly higher at approximately 35% in Q3 and Q4 due to the reduction in United States profitability, and as always, subject to no significant change in our valuation allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">5</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Turning now to our balance sheet. Our cash, cash equivalents and investments available for sale as of June
30, 2023, totaled $209.5&nbsp;million as compared to $225.5&nbsp;million at the end of the fourth quarter of 2022. The decrease in overall cash is due to the timing of accounts receivable, which historically grows in the second quarter and should be
converted to cash in the third quarter. Though we have only booked approximately $6 million in CapEx at the end of Q2, we continue to expect we will invest approximately $26&nbsp;million in property and equipment for the full year, primarily related
to manufacturing capacity expansion, including some larger projects in the second half of this year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Tom mentioned earlier, today we updated our ICL
net sales outlook to a range of $320&nbsp;million to $325&nbsp;million for fiscal 2023. We expect our other product sales will be essentially 0 for the full year fiscal 2023 due to the cataract IOL business adjustments I had referenced previously. A
reconciliation to the midpoint of our outlook results in an approximate $22&nbsp;million change from our prior ICL outlook. This includes an approximate $12&nbsp;million lower sales contribution from the United States, approximately $5&nbsp;million
lower sales contribution for EMEA, or flat sales year-over-year, and an approximate $5&nbsp;million reduction in sales from certain APAC markets, primarily South Korea, which has faced some economic headwinds. For Q3 2023, we expect global ICL sales
and overall net sales will be approximately $80&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Next week, STAAR will be participating in the Canaccord Genuity Annual Growth Conference in
Boston on August 9. We will also be participating in the Needham Virtual MedTech and Diagnostics Conference on August 15, the Piper Sandler West Coast Bus Tour on August 23, the William Blair West Coast Bus Tour on August 30; and the Goldman Sachs
Annual European MedTech and Healthcare Services Conference in London on September 6. And as Tom mentioned, on Thursday, September&nbsp;14, STAAR will host an Investor and Analyst Meeting in New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, we intend to use our website as a means of disclosing material, <FONT STYLE="white-space:nowrap">non-public</FONT> information and for complying with
our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the Investor Relations section. Accordingly, investors should monitor our investor website in addition to following our press releases, SEC filings
and public conference calls and webcasts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This concludes our prepared remarks. Operator, we are now ready to take questions. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>QUESTIONS AND ANSWERS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Operator Instructions) Your first question comes from Bill Plovanic from Canaccord. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It&#146;s John on for Bill tonight. I think you could start on the U.S., which I think is maybe the most &#151; what everyone&#146;s focused on. I appreciate
all the detail that you gave there, Tom. But with the sequential flat to decline revenue, and I know you&#146;ve made previous commercial investments there, too, beyond just adding Warren as COO. But can you talk about just when do you expect
productivity from those commercial adds to ramp? I know you talked about potentially expecting it in the back half of this year, but just any incremental detail of what you&#146;re seeing there, and also just what you&#146;re hearing from surgeons?
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. Thanks, John, and good to hear from you. Give our best to Bill as well. I think, look, we said all along that laser vision correction is very well
entrenched in the United States market. We&#146;ve talked about the inertia of LASIK. And I think until we move EVO from a niche procedure to a more mainstream in a given refractive practice, it&#146;s just going to take time. But we believe we
better understand the market today as we&#146;ve made some investments in new analytical tools and certainly putting more feet on the street and getting candid feedback. So we remain very optimistic about it as we execute on the vital few projects
that we&#146;ve identified that we believe in the U.S. can create breakthrough opportunities, we&#146;re going to be just fine. I&#146;ve said all along and as late as June, it was an <FONT STYLE="white-space:nowrap">18-</FONT> to <FONT
STYLE="white-space:nowrap">24-month</FONT> process, and I think we&#146;re still working on that same timeline. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">6</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Great. And just for a <FONT STYLE="white-space:nowrap">follow-up,</FONT> too. I was a bit surprised on the commentary about the digital marketing not working
out as you had anticipated. What do you think isn&#146;t working correctly there? Because it seems like it&#146;s had good patient traction. Is it that these patients who become aware of the procedure are seeing physicians who are not aware of EVO
and then get converted to other procedures? Or what do you think the hiccup is in that? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company -
President, CEO&nbsp;&amp; Chairman </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. I think you do see some of that bait and switch happening in the marketplace. And again, we said all along, the
beauty of digital marketing is you can redirect it, you can turn it off, you can turn it on, and that&#146;s exactly what we&#146;re doing. I think we&#146;re just being more prudent about where we&#146;re spending the money. And I think a great
example of that is the call center project that we&#146;re initiating in the back half of this year because it really gives us for the first time the opportunity to create this closed loop as a result of our Doc Finder. You&#146;ve heard us talk
very positively about the amount of traffic we&#146;re seeing on the Doc Finder, but it&#146;s always been a challenge to understand what happens to those patients. And now through this process, we&#146;re going to know exactly what&#146;s
happening, and we&#146;re going to be able to direct interested patients to an appropriate EVO center where we know they&#146;re going to be treated well. So again, I think we&#146;re just a little smarter, a little wiser, and we&#146;re being a
little bit more prudent about how we&#146;re going to spend those digital dollars. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your next question comes from Anthony Petrone from Mizuho Group. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anthony Charles Petrone </B>- Mizuho Securities
USA LLC, Research Division - MD&nbsp;&amp; Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maybe one for Tom on guidance and
then a <FONT STYLE="white-space:nowrap">follow-up</FONT> just on balance sheet for Patrick. So maybe Tom, just walking through the shift here to $20 million to $23&nbsp;million revision in total from the prior range. You sort of look at the 2Q
performance. China was actually ahead of our expectations. Light in the United States. It was also light in Japan. So when we reconcile the quarterly performance of the guidance, is it mostly just U.S., or are we splitting that between Japan and
U.S.? Or should we also be taking a little bit of deceleration into the back half of the year for China as well? And I&#146;ll have one <FONT STYLE="white-space:nowrap">follow-up.</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. No. Thank you, Anthony, for the question. I think you&#146;re right. We see a little bit of softness, as Patrick in his prepared remarks called out South
Korea in particular, Japan to a little lesser degree, a little softer. We think China will continue to grow. As I mentioned in my prepared remarks, very encouraged by the first month, 1.5 months of the high season. That&#146;s really off to a
phenomenal start. So I think China will continue to show that kind of growth. But again, globally, we believe we&#146;re a 20% per year growth company. We continue to be a high-growth organization. And I think that will continue beyond 2023,
particularly as we begin to execute on these vital few projects. So I think a 20% top line growth is always going to be our goal and hopefully beyond that as we execute on these priorities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anthony Charles Petrone </B>- Mizuho Securities USA LLC, Research Division - MD&nbsp;&amp; Senior Medical Devices, Diagnostics and Therapeutics Equity
Research Analyst </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All right. That&#146;s helpful. And then the <FONT STYLE="white-space:nowrap">follow-up</FONT> for Patrick, maybe just on the AR balance.
Understand the seasonality here. I guess sequentially, it&#146;s up $34&nbsp;million. In the prior 2 years, it was up about $15&nbsp;million <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Q-over-Q</FONT></FONT> from 1Q to 2Q. So
maybe just walk through the outsized increase in receivables this cycle <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-a-vis</FONT></FONT> the prior 2 cycles. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">7</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company - CFO </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes, sure. It&#146;s a little higher. Some of it has to do with just the timing of product as we delivered into the various markets, primarily into Asia
Pacific. No issues with collectability. We&#146;ll look to see that number go quite a bit down in Q3 as we monetize or convert that AR into cash. So we&#146;re in good shape there. Inventory levels are very good across all of our regions, including
APAC. And so we&#146;re feeling very good about where we&#146;re at from all those standpoints. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your next question comes from Margaret Kaczor from William Blair. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Malgorzata Maria Kaczor Andrew </B>- William
Blair&nbsp;&amp; Company L.L.C., Research Division - Partner&nbsp;&amp; Research Analyst </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first one I want to ask about is the U.S., like many of my
colleagues. But I&#146;m trying to do the math. It seems like you&#146;re sort of assuming relatively flat sales here, I guess, sequentially through <FONT STYLE="white-space:nowrap">year-end,</FONT> so maybe you can true me up on that. And as we
think about that decrease down, certainly, you&#146;re maybe not seeing the ROI on some of the elements you expected, but how do you think about the macro element here? And second, how much success, if any, are you assuming in terms of measures that
Tom mentioned, like the call center, especially as we get into Q4? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Margaret, this is Tom. Thank you for the question. First, to answer the first part of your question, yes, I think it&#146;s not unreasonable to assume
we&#146;re relatively flat back half of the year for the U.S. as these priorities take shape and we move full bore into an execution phase. So I think that&#146;s not unreasonable for you to expect. But I think, again, the U.S. business, as
I&#146;ve said all along, is just going to take some time. But I think as we focus in on enhanced training, additional clinical and medical education efforts that we have going on, looking at things driving surgeon confidence at a higher level, they
will all bear fruit in 2024 and beyond. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company - CFO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes.
I&#146;ll just piggyback off of that. So just to get to the guidance in general, because I think we&#146;ll get a lot of questions on this. The programs and the initiatives that we outlined do not contemplate those having material traction in the
second half of 2023, as we&#146;ve said. And I think when we talked about all the markets, we did a bridge, at least in my prepared comments, from the old guidance to the new updated guidance. We wanted to put a number out there that we feel very,
very confident about, and that&#146;s the number that you&#146;re getting between that $320&nbsp;million and that $325&nbsp;million for the full year. And it takes into account all the stuff that we talked about. And as always, some of these things
get a little traction earlier, then potentially we can see some upside to that. But this is, in our minds, a very, very achievable number. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Malgorzata Maria Kaczor Andrew </B>- William
Blair&nbsp;&amp; Company L.L.C., Research Division - Partner&nbsp;&amp; Research Analyst </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Okay. That&#146;s helpful. And then I know we&#146;re sitting
here in <FONT STYLE="white-space:nowrap">mid-2023,</FONT> so it&#146;s not really fair of me to ask this question, but I&#146;ll ask it anyway. As we look at 2024, I guess, can you walk us through what gets you to that 20% top line growth between
the different geographies? Especially if we&#146;re going to exit the U.S. around that $4&nbsp;million, let&#146;s say, revenue number, what&#146;s kind of the gap to get to that 20%? And then second, as we think about margin expansion, I assume we
will see some of that in 2024 with 2023 being a low watermark. So how are you guys thinking about that expense structure? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">8</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company - CFO </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes, I&#146;ll jump in. It&#146;s a fair question. The 20% is clearly a 2023 number. We&#146;re not going to get into 2024 and beyond. We clearly have an
Investor Day coming up. I think it&#146;s fair to say that internally, we continue to view ourselves as a high-growth company. However you define that, that 15% to 20% range is probably about right. And as I said, that number could go higher. We
could be on the high end of that range as some of these programs that we&#146;re putting together come to fruition. And so based off of the new outlook that we provided for 2023, which we feel is very achievable, I think as people think about going
beyond that, as I said, that 15% to 20% probably makes sense. But we&#146;ll provide more details as we get more visibility to these things, and we have the opportunity to really set the stage more so at our Analyst Day on September 14. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your next question comes from Young Li from
Jefferies. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Xuyang Li </B>- Jefferies LLC, Research Division - Equity Analyst </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I guess you have a lot of ongoing initiatives focused on the U.S. launch. I was wondering, by the Analyst Day, what do you think you can share with us related
to the trajectory of the U.S. launch? And can you give us a preview for what we should expect to hear, sort of maybe more longer-term information out of the Analyst Day? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company -
President, CEO&nbsp;&amp; Chairman </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes, Young. This is Tom. Thanks for the question. I think as we said, we continue to give guidance for this year at
20%. We believe we will continue to be a high-growth company beyond 2023 in the 15% to 20% range. And we think to the degree that as we execute on these initiatives, it could go higher. In September, I think you&#146;ll be able to hear more
granularity both from us as well as from some leading KOLs that will join us in New York to talk about their own individual expectations and how EVO is impacting their practices. And we believe that these will be global KOLs that represent not only
U.S. but Europe and Asia Pacific regions. So I think more to come. I think it&#146;s going to be an exciting discussion. And many of the questions that you all are asking already will be fully answered in September. So I hope you make the time to
join us in New York. It&#146;s going to be an exciting time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Xuyang Li </B>- Jefferies LLC, Research Division - Equity Analyst </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All right. Great. Looking forward to that. Maybe to follow up just on China. Pretty strong performance in second quarter. Heard the comments on the strong
start to the peak season, but we see a lot of the negative macro headlines coming out of China. So just wanted to put a finer point on the level of confidence on China performance in the second half. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes, Young. I can tell you firsthand, having just spent 10 days in China across 3 different markets within that country, enthusiasm is high, activity is high,
surgeon support and surgeon confidence is high. I&#146;ve met with economists there as well as clinicians. And there&#146;s a bullishness there at the street level that I felt, that I saw. And I continue to be extremely confident in the quality of
our team and the quality of the level of activity we&#146;re seeing in that market. Again, through really half of June and all of July, our <FONT STYLE="white-space:nowrap">in-market</FONT> sales are really at a very, very strong level. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your next question comes from Ryan Zimmerman
from BTIG. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is Sam on for Ryan. Could you
give us an update on the geographic unit growth that is implied with your new 2023 guidance? </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">9</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company - CFO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes,
I don&#146;t think we get into many specifics on that, but it will be pretty close. It might be slightly above that from a unit standpoint because we do see, depending on geographies, a little bit of mixture right on the ASP. So we might have maybe
1% or 2% higher than on the unit growth when it&#146;s all said and done, but it should be pretty close to the 20%. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">That&#146;s helpful. And it sounds like China is performing very well. How have ASPs in China trended throughout the year, and how do you expect those to trend
in the second half of the year? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I&#146;m sorry, Sam. How is what trending? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">How have ASPs trended in China this year? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company -
President, CEO&nbsp;&amp; Chairman </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strong. No price degradation. No real pressure on price, if that&#146;s what you were asking. Again, having just spent
time there on the street myself, I can tell you we&#146;re holding price heavy. We continue to be positioned as a premium choice, and the market&#146;s reacting favorably. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company -
CFO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. Just as a reminder for everyone, we don&#146;t have one single price for China. It&#146;s a byproduct of multiple customers that we have there
that have different pricing, as well as the fact that we sell Spheric and Toric lenses, which have different pricing as well. So we know our pricing, and it&#146;s set for basically the entire year. Any change that you see is really due to product
mix and/or customer mix within the selling into that throughout the year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your next question comes from Matt O&#146;Brien from Piper Sandler. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is Sam on for Matt. I guess first, could you talk a little bit about stocking in China in the second quarter compared to a year ago? And also, are there
any signs of moving down the diopter curve during the quarter? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company - CFO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes.
Like I said, the inventory levels are good in China. As always, as the market share continues to grow in China &#151; and not just China; other markets &#151; we might look to further increase our service levels, as we like to say, meaning we want
to make sure inventory&#146;s much closer to the physician and those end user patients so that we can make sure that EVO happens as rapidly as possible. But nothing unusual with Q2. It is our high season where we sell in, and then a high season in
terms of implants and procedures starts really in that July time frame and continues through August and maybe a little in September. So as I said, we&#146;re very comfortable with where we&#146;re at on an inventory level across the globe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">10</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And relative to the diopters, I would say, anecdotally, we certainly have heard and seen examples of surgeons globally coming down the curve. I would say in
aggregate, as we look at it internally, there&#146;s been about a 0.5 a diopter to a 1 diopter movement down in our aggregate numbers. But more and more, I think individual docs are certainly starting to make moves bigger than that. A good example
of that, again, from a KOL here in the United States who has gained a high degree of confidence now. His whole marketing effort is going to be around EVO, and he has indicated that he&#146;s going to be very comfortable offering EVO to anyone minus
3 or above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">That&#146;s great. I guess one more
question to ask. And I know you all have mentioned being very confident in your updated guidance. And I guess, could you give us like what gives you that confidence in your updated guidance, and exactly when all does that all begin? </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. As I tried to indicate in my prepared remarks, I&#146;ve spent a lot of time in the field around the world, but also particularly here in the United
States. And in talking with key opinion leaders, east, west, north and south, I just continue to be encouraged by the positive rhetoric, the commitment people have to the technology, trying to find ways to fit it into their practices on a more
routine basis to move it out of a niche mindset and more into the mainstream. And as we better understand the nuances of these practices and how we can help them achieve the kind of position that EVO deserves in their practice, I remain confident
that we&#146;re going to be able to make that happen. One of our prescriptive visions, our mantra in the company is to become the first choice of patients and doctors who are seeking visual freedom. And we&#146;re on our way. That&#146;s
aspirational. We&#146;re doing all the right things to make that happen. But we know today, we&#146;re not the first choice. But that&#146;s our aspirational goal, and the organization is highly focused on achieving that. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And your next question comes from George
Sellers from Stephens Inc. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is Harrison on for George. My
first is on the U.S. refractive market down 15% year-over-year. I was wondering if you all had any idea of the drivers there. Is that a macroeconomic issue? Or is there something else going on in the offices that we need to be aware of? </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. I don&#146;t think there&#146;s anything unusual that&#146;s happened. But the Refractive Surgery Council here in the United States tracks that pretty
routinely, and they just came out with their Q2 assessment, and it&#146;s down 15%. And again, we&#146;re not pleased with where the U.S. growth is, but I think it&#146;s worth noting again that we were up 10% in a market that&#146;s down 15%. So we
know we&#146;re having impact. It&#146;s not maybe at the level you all wanted to see. It&#146;s certainly not at the level we want to see. And we&#146;ve got plans in place to know that it&#146;s going to improve. So I think when you put it in the
context of what&#146;s happening in the laser vision correction market in general, our performance in Q2 is certainly beating the market. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">11</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Got it. Yes, that&#146;s helpful. And then switching over to China, I&#146;m just curious. I know you&#146;ve spoken about moving down the diopter curve there,
but I was just wondering how patients were responding, just given the elevated price compared to LASIK. And are they really recognizing that the clinical benefits and the better medicine that you all have and they&#146;re willing to pay for that? Is
that something you&#146;ve all seen? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. Again, firsthand, there are 11 <FONT STYLE="white-space:nowrap">EVO-only</FONT> centers across China where all they do is EVO surgery at a premium price.
So again, people see the outcome. The patient satisfaction, as we&#146;ve previously reported, continues to be at 99% to 99.5% high patient satisfaction. So clearly, price is always an issue for a certain type of patients. But overall, price has not
been an obstacle to our growth, particularly in that marketplace. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your next question comes from the line of Tom
Stephan with Stifel. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas M. Stephan </B>- Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, Research Division - Associate </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And sorry if some of these were asked. Jumping between calls. But I&#146;ll start with just on the financial side. Profitable high growth really has been a
differentiating aspect of STAAR&#146;s financial profile for many years now. This year, operating margin obviously is expected to step back a bit from last year. But I guess big picture, can you talk philosophically about if the thinking has changed
at all about the focus? And I guess those very high levels of profitability, and whether maybe the thinking is shifting more toward growth, just given the early stages of ICL penetration globally and more notably in the U.S. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes, Tom, thanks for the question. Good to hear from you. I think, look, we have to serve both masters, right? We want to grow top line and we want to continue
to grow bottom line. But as we&#146;ve said in the past, we have a strong balance sheet, and we want to leverage that balance sheet. We&#146;ve made some investments in the first part of this year. We knew it would compromise our bottom line, but we
continue to be profitable on the bottom. We believe generating high growth is preferable, and we&#146;re going to continue to focus on continuing to be a high-growth company this year and beyond. But we&#146;ll be fiscally prudent and disciplined
about how we spend that balance sheet. So I&#146;ll let Patrick add a little bit more color, but we&#146;ll continue to focus on both, but our emphasis will be on continuing to drive top line growth. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company - CFO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes.
Thanks, Tom. And so I think I talked a little bit about gross margins. As we continue to see very good gross margins and as we bring on these direct markets like the U.S., like some of the direct markets in Europe, that&#146;s only going to help
give us a tailwind on our overall gross margin by raising our ASPs. As you know, whenever you&#146;re launching in a new market, especially a direct market, you&#146;re going to have a little bit more infrastructure and investment that you do at the
beginning, i.e., our sales force that we did at the beginning of the year. And so we&#146;re laying the groundwork for that. We&#146;ll talk more about this in September at our Analyst Day. But internally and as we look at it, we don&#146;t see any
issues with being able to continue to have some good bottom line performance. But no doubt, we want to make sure that we are taking market share wherever we can, and we realize that we have a really good opportunity here, especially with being the
leading lens-based product out there to really drive market share across the globe. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">12</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas M. Stephan </B>- Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, Research Division - Associate
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Got it. That&#146;s helpful. And then to pivot to the United States, I actually want to ask kind of longer term. In the past, the company talked about 20%
share maybe as soon as the 2025 time frame. Maybe that&#146;s pushed out a little bit. But can you speak to your level of confidence in ultimately achieving a number like that longer term, kind of no matter however many years that may take? And
maybe more importantly and the crux of my question. Tom, can you just talk to what you believe the main foundational and big picture challenges in the U.S. market are, whether it&#146;s infrastructure? &#151; I&#146;ll let you answer that. But more
importantly, what STAAR is doing to solve those problems or I guess lower those hurdles. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company -
President, CEO&nbsp;&amp; Chairman </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. Thanks again for the <FONT STYLE="white-space:nowrap">follow-up</FONT> question. Look, as I mentioned earlier in
the call, I think, look, we need to move EVO beyond a niche mindset in the minds and hearts of many ophthalmologists. And clearly, the challenge we have is moving EVO into the mainstream of their practice. One of the ways we&#146;ll do that is
taking some of the art out of the procedure and putting more science and predictability into the procedure. And we&#146;re going to do that through a real focus on enhanced training, additional independent medical education as well as investigator
initial trials that we&#146;re looking at. We&#146;re exploring some other intermediate sizes to address some of the concerns we&#146;ve heard about from doctors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So I think all in all, I am confident because people like the outcomes that the procedure drives. The procedure is not difficult, but it&#146;s delicate. And
that delicate portion equates to a little more art than science compared to a nomogram rote procedure that laser vision correction has become. And I think we&#146;ve learned through these first 7 months, some issues that we need to focus on to make
this a little bit more predictable in the hands of any surgeon, whether you&#146;ve done 10 or whether you&#146;ve done 10,000. And I&#146;m confident that we&#146;re smarter today than we were in January. As I said, we have these vital few projects
that focus on a lot of these areas, cross-functional teams that wake up every day working on how we improve those areas. And we&#146;re beginning now to get to the execution phase that I think will carry us through this year, keep the U.S. business
moving forward, keeping our growth engines outside the United States moving forward and sets us up for a consistent high-growth company for 2024 and beyond. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your next question comes from David Saxon from Needham. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>David Joshua Saxon </B>- Needham&nbsp;&amp;
Company, LLC, Research Division - Senior Analyst </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I guess maybe starting on the U.S. At the ASCRS conference, we picked up delivery times can be around 6
weeks. I&#146;m sure that varies. But you obviously called that out as something you&#146;re working on. So I wanted to ask, what specifically needs to be done on that front? And how quick do you think you can get the order to delivery time? </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. No, I appreciate that question, Dave. As we&#146;ve said, one of our initiatives is really dealing with manufacture and operations ability to deliver
product quicker to the customer. I think right now, our inventory levels are such that we&#146;re doing extremely well and beating that <FONT STYLE="white-space:nowrap">6-week</FONT> period of time. I think as we can move more and more closer to,
let me say, like a LASIK-like outcome for delivery where a patient walks in the door and certainly within a matter of days can be treated, that&#146;s our ultimate goal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>David Joshua Saxon </B>- Needham&nbsp;&amp;
Company, LLC, Research Division - Senior Analyst </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Okay. Got it. And then the EMEA country that you can&#146;t ship to anymore, maybe give a little more
color on that. How much impact was that in the quarter? And that $5&nbsp;million guide down as it relates to the EMEA region, is that all related to this one country? Or does that assume kind of slower growth across the broader EMEA region? </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">13</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sure, David. I think suffice to say, the countries in the Middle East, I think if that order would have went through, we probably would have had the region
almost flat. So you can do the math and figure that out. Certainly, our direct markets, and as I said, in Europe, Europe specific was up in Q2. Not significantly, but 6% and 2%, respectively, relative to sales and units. So they&#146;re holding
their own. But clearly, we have opportunities for growth in Europe and EMEA across the board. But I&#146;ll let Patrick add any other more color he&#146;d like to to those numbers. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company - CFO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No, I
think Tom hit it. So I think we&#146;re good, and we did take down a little bit on guidance. But as I said before, we wanted to put a number out there globally that we felt very comfortable with. And in my prepared comments, we try to do and give a
lot of transparency on bridging the old guidance to the new guidance. And as everyone can see, a big part of the underperformance and the lowering is related to the U.S. But we&#146;re coming off a record breaking Q2. And as I said, we feel good
about what we&#146;re doing and where we&#146;re going to end up the year and where we move forward. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your next question comes from Jim Sidoti from Sidoti&nbsp;&amp; Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James Philip Sidoti </B>- Sidoti&nbsp;&amp;
Company, LLC - Research Analyst </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Just want to follow up. You said you are going to scale back on some of your digital marketing until you figure out a more
efficient strategy. But you also said you&#146;re going to still continue to ramp up the capital spending for 2023. So should that &#151; does that imply that you still think you can become a 15% to 20% &#151; win 15% to 20% market share in the
U.S.? You still think that you&#146;ll need that capacity over the next couple years? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company -
CFO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. So you&#146;re absolutely right. And to be clear, we are reallocating some of our spend on the sales and marketing, as Tom said. But we clearly
want to make sure that as we&#146;re making these investments, we&#146;re getting the type of return we want. We will revisit this as some of these programs and initiatives related to our vital few come through. The CapEx, I think that&#146;s a good
observation on your part, Jim. I mean, we continue to be very bullish about what our prospects are, and we have to start planning capacity now for what will be higher market share globally in all of these geographies. So yes, we are spending the
money to build out our capacity, et cetera. So we believe very strongly in EVO, and it should be the first choice for customers and their patients seeking visual freedom. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James Philip Sidoti </B>- Sidoti&nbsp;&amp;
Company, LLC - Research Analyst </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And again, I think other analysts may have asked this. But you still think long term, you can be at least a 15% market
share in the U.S.? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company - CFO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I
think more to come during the Analyst Day. But I think we&#146;ve said it a couple times now that we view ourselves internally as high growth, and we think that&#146;s between 15% and 20% and more to come as we show some of the pathway to get there.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">14</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your next question comes from Steve Lichtman from Oppenheimer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steven Michael Lichtman </B>-
Oppenheimer&nbsp;&amp; Co. Inc., Research Division - MD&nbsp;&amp; Senior Analyst </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I was wondering on the vital few, Tom. In terms of some of the projects
you have underway, you talked about simplifying ordering process, things like that. How should we think about the implementation time of those? When do you anticipate them sort of being up and running? </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Well, some are up and running now. Some will kick in, in Q3 and Q4. But certainly, throughout the back half of this year, every one of our priorities will be
in various forms of execution, which is why we&#146;re saying it&#146;s going to create a tailwind for us through the balance of this year and set us up for a very solid 2024. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steven Michael Lichtman </B>- Oppenheimer&nbsp;&amp; Co. Inc., Research Division - MD&nbsp;&amp; Senior Analyst </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Okay. And then just as a <FONT STYLE="white-space:nowrap">follow-up.</FONT> Can you talk to a little bit more detail on the call center? What sort of pressure
point in the field do you think that that will help address? And how big do you expect that initiative to be? </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company -
President, CEO&nbsp;&amp; Chairman </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Time will tell. We&#146;re doing a test pilot, and then we&#146;re going to expand it to regions of the country as
opposed to nationally while we grow together. We&#146;re working with a third party who certainly has a successful track record in this area. And I think as I indicated earlier, we know through our Doc Finder, we&#146;re continuing to get consistent
visits. But a lot of those visits, you lose visibility to what happens to them after they come and try to find a doc in their particular area. This is now taking back control of that. And through this call center, we&#146;ll be able to communicate
with these patients, really understand their motivation, are they ready to have a procedure. And then direct them to the appropriate practices that we know a bait and switch won&#146;t go, and they&#146;ll be more than likely turned into surgical
procedures. So again, as I said, it&#146;s creating a little closed loop so we can create a cause and effect relative to the dollars we spend generating brand awareness, driving people to a Doc Finder website and then funneling those patients
appropriately. That was not happening until we&#146;re turning on this call center. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our last question for today comes from Bruce Jackson from The Benchmark Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bruce David Jackson </B>- The Benchmark Company,
LLC, Research Division - Senior Equity Analyst </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I wanted to see if I could get some color on the decline in Japan and Korea. How much of that was due to
the discontinuation of the other products, and how much was due to just general market conditions? And do you still think that Japan and Korea can be up for the year in total? </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick F. Williams </B>- STAAR Surgical Company - CFO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes.
Thanks for asking that, Bruce, because I think it&#146;s important everyone understands that within our Japan breakout that we do on our disclosures of our <FONT STYLE="white-space:nowrap">10-Q</FONT> and our K, that does include other products and
a pretty significant amount of it. As you know, we&#146;re not &#151; we&#146;re basically doing nothing in Q2 related to the IOL. Japan itself was actually up year-over-year on the ICL business. And so overall, what we&#146;re seeing is a little
bit of pressure, as I said, in South Korea, maybe a little bit in Japan, but that equates to that $5&nbsp;million takedown that we did related to APAC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">15</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUGUST 02, 2023 / 8:30PM, STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I will now turn the call back over to Tom
Frinzi for closing remarks. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas G. Frinzi </B>- STAAR Surgical Company - President, CEO&nbsp;&amp; Chairman </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for joining our call today. We look forward to speaking with many of you in the coming days and weeks, including next month at our New York Investor
and Analyst Meeting. Thank you. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and gentlemen, this concludes your
conference call for today. We thank you for joining, and you may now disconnect your lines. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:1%; margin-right:1%; font-size:10pt; font-family:Times New Roman"><B>DISCLAIMER </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1%; margin-right:1%; font-size:10pt; font-family:Times New Roman">Refinitiv reserves the right to make changes to documents, content, or other information on
this web site without obligation to notify any person of such changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:1%; margin-right:1%; font-size:10pt; font-family:Times New Roman">In the conference calls upon which Event
Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current expectations and involve risks and uncertainties. Actual results may
differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically identified in the companies&#146; most recent SEC filings. Although the companies may indicate and
believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking
statements will be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:1%; margin-right:1%; font-size:10pt; font-family:Times New Roman">THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE
APPLICABLE COMPANY&#146;S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES REFINITIV
OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY&#146;S CONFERENCE CALL
ITSELF AND THE APPLICABLE COMPANY&#146;S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS. </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; margin-left:1%; margin-right:1%; font-size:10pt; font-family:Times New Roman">&copy;2023, Refinitiv. All Rights Reserved. </P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&copy;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without
the prior written consent of Refinitiv. &#145;Refinitiv&#146; and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">16</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g522240dsp03.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>staa-20230802.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 8/4/2023 12:39:50 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:staa="http://www.staar.com/20230802"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.staar.com/20230802"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20230802_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20230802_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>staa-20230802_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 8/4/2023 12:39:50 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>staa-20230802_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 8/4/2023 12:39:50 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="staa-20230802.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g522240dsp03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522240dsp03.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MQ'W!^H% &E\"M%:P\"MJ<Z_Z3JD[3LQZE>@_J?QH ]0H I:O_P @6^_ZX/\
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3N <9KL6.Q"H^PYWR]@-NN,#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916639505648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">STAAR SURGICAL CO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000718937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  02,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-11634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3797439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25651 Atlantic Ocean Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lake Forest<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">303-7902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">STAA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d522240d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="staa-20230802.xsd" xlink:type="simple"/>
    <context id="duration_2023-08-02_to_2023-08-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000718937</identifier>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2023-08-02_to_2023-08-02"
      id="Hidden_dei_EntityRegistrantName">STAAR SURGICAL CO</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2023-08-02_to_2023-08-02">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-08-02_to_2023-08-02"
      id="Hidden_dei_EntityCentralIndexKey">0000718937</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-08-02_to_2023-08-02">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-08-02_to_2023-08-02">2023-08-02</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-08-02_to_2023-08-02">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-08-02_to_2023-08-02">0-11634</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-08-02_to_2023-08-02">95-3797439</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-08-02_to_2023-08-02">25651 Atlantic Ocean Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-08-02_to_2023-08-02">Lake Forest</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-08-02_to_2023-08-02">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-08-02_to_2023-08-02">92630</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-08-02_to_2023-08-02">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-08-02_to_2023-08-02">303-7902</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-08-02_to_2023-08-02">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-08-02_to_2023-08-02">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-08-02_to_2023-08-02">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-08-02_to_2023-08-02">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-08-02_to_2023-08-02">Common</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-08-02_to_2023-08-02">STAA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-08-02_to_2023-08-02">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-08-02_to_2023-08-02">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #V% U<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  ]A0-7=*KI,>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O;15&:'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN
M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I#
M'1!JSN_!(2FC2,$$+,)"9+(U6NB(BOIXQAN]X,-G[&:8T8 =.O24H"HK8'*:
M&$YCU\(5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.31S+N]0P=O3X\N\;F%]
M(N4UYE_)"CH%7+/+Y-?F8;/;,EGSNBGXJN#-KN;BMA)WJ_?)]8??5=CUQN[M
M/S:^",H6?MV%_ )02P,$%     @ /84#5YE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M3A8[F6$6TB$2>,'%<.11C*A9#7S<Q+\I80S/(#%I6F0' ]&M5+A0U]KM-XN
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  ]A0-7EXJ[',     3 @
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    "  ]A0-7!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #V% U=TJNDQ[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( #V% U>97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ /84#5\\Z5'(^!   <1   !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( #V% U>?H!OPL0(  .(,   -              "  8(,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ /84#5Y>*NQS     $P(   L
M     ( !7@\  %]R96QS+RYR96QS4$L! A0#%     @ /84#5QPX9>H_ 0
M/ (   \              ( !1Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( #V% U<D'INBK0   /@!   :              "  ;,1  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #V% U=ED'F2&0$  ,\#
M   3              "  9@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(  .(3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d522240d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  d522240d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d522240d8k.htm">d522240d8k.htm</File>
    <File>d522240dex991.htm</File>
    <File>staa-20230802.xsd</File>
    <File>staa-20230802_lab.xml</File>
    <File>staa-20230802_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d522240d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d522240d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "staa-20230802_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "staa-20230802_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "staa-20230802.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "staa",
   "nsuri": "http://www.staar.com/20230802",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d522240d8k.htm",
      "contextRef": "duration_2023-08-02_to_2023-08-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d522240d8k.htm",
      "contextRef": "duration_2023-08-02_to_2023-08-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-23-202937-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-202937-xbrl.zip
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MH:=WMKM-'P[<FI%9G)LX03]^'Y^/PZV=Y@F9530-;H]'KXL,X05[_*@GT#X
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MDD=S)2,M>>WL+F1]![O68X)NH+9\9V1 R!<3W7NX_8C%2QV_T60%:-^T>SA
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M[)M]^@]+_@)02P$"% ,4    "  ]A0-7:+U.CO,.  "98   #@
M    @ $     9#4R,C(T,&0X:RYH=&U02P$"% ,4    "  ]A0-7 52(*7Y8
M  #[X@$ $0              @ $?#P  9#4R,C(T,&1E>#DY,2YH=&U02P$"
M% ,4    "  ]A0-7,V3L;3H#  !#"P  $0              @ ',9P  <W1A
M82TR,#(S,#@P,BYX<V102P$"% ,4    "  ]A0-7':G#;F$&  "^0P  %0
M            @ $U:P  <W1A82TR,#(S,#@P,E]L86(N>&UL4$L! A0#%
M  @ /84#5P1<0)6S!   =BH  !4              ( !R7$  '-T86$M,C R
C,S X,#)?<')E+GAM;%!+!08     !0 % $ !  "O=@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
